NCT01813318View on ClinicalTrials.gov

Study of Acamprosate in Autism

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 2, 2013

Primary Completion Date

September 7, 2017

Study Completion Date

September 7, 2017

Conditions
Autistic Disorder
Interventions
DRUG

Acamprosate

The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.

DRUG

Placebo

Subjects receiving placebo will be dosed similarly to the acamprosate group.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Autism Speaks

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01813318 - Study of Acamprosate in Autism | Biotech Hunter | Biotech Hunter